STADA Arzneimittel AG
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From STADA Arzneimittel AG
New products from Paion, Arvelle, Incyte and many others have been recommended for approval by the European Medicines Agency. Meanwhile, the agency has explained why the EU marketing authorization application for Dexamethasone Taw, for treating COVID-19 patients, was withdrawn.
Nidda Healthcare, investment vehicle controlled by Bain Capital and Cinven, secured a “timely” squeeze-out of minority shareholders in Stada through settlement terms that include a one-time payment of 10 euro cents per outstanding share for the remaining shareholders.
Nidda Healthcare, the investment vehicle controlled by Bain Capital and Cinven, has secured a “timely” squeeze-out of minority shareholders in Stada through settlement terms that include a one-time payment of €0.10 per outstanding share for the remaining shareholders.
Strides files for a biosimilar to Eli Lilly’s Forteo (teriparatide) in the EU, marking the beginning of its journey in the biosimilars segment. Meanwhile, it hopes to enter a manufacturing tie-up with COVID-19 vaccine players in H2 while also planning a launch of favipiravir in markets outside India.
- Generic Drugs
- OTC, Consumer
- Other Names / Subsidiaries
- Bain Capital
- BIOCEUTICALS Arzneimittel AG
- Britannia Pharmaceuticals Limited
- Forum Bioscience Holdings, Ltd.
- Laboratorio Vannier S.A.
- Nidda Healthcare
- STADAPHARM GmbH
- LobSor Pharmaceuticals AB